Integrated BioPharma Q1 net loss of $35K vs net income $516K YoY; revenue down 3% to $12.3M

INTEGRATED BIOPHARMA INC

2023-Q1 EPS reported $0.00 revenue$12,326,000

Revenue $12.3M, down ~3.1% from $12.8M in Q1 FY2022.
Operating income fell to $30K from $585K in the year-ago quarter.
Net loss of $35K ($0.00 EPS) vs net income of $516K ($0.02) in Q1 FY2022.
Two largest Contract Manufacturing customers were 85% of revenue (down from 91%).
Co-CEOs cite pandemic overstocking by customers as key headwind.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTEGRATED BIOPHARMA INC reported the quarter ended September 30, 2022 results: revenue $12.3 million, net income net loss of approximately $35,000 or $0.00 per share of common stock, EPS $0.00 per share of common stock.

Period: the quarter ended September 30, 2022
Revenue: $12.3 million
Net income: net loss of approximately $35,000 or $0.00 per share of common stock
EPS: $0.00 per share of common stock
Result: reported results

Exact text from the filing

Integrated BioPharma Reports Results for its Quarter Ended September 30, 2022 HILLSIDE, NEW JERSEY (November 10, 2022) - Integrated BioPharma, Inc. (OTCQX: INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2022. Revenue for the quarter ended September 30, 2022 was $12.3 million compared to $12.8 million for the quarter ended September 30, 2021, a decrease of $0.5 million or approximately 3.1%.

View on SEC.gov

Browse all earnings releases →

INTEGRATED BIOPHARMA INC filing history →

Source: SEC EDGAR

accession 0001437749-22-027168

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.